A recent U.S. study has highlighted a significant and concerning issue in asthma care: racial and ethnic disparities in access to and use of asthma inhalers. Despite clear medical guidelines recommending daily controller inhalers as the most effective long-term treatment for asthma, people from Black, Hispanic, and Asian communities are less likely to use them compared with white patients.
The findings raise important questions about healthcare access, socioeconomic inequality, and long-term disease management in chronic respiratory conditions such as asthma. The research was published in the Journal of the American Medical Association.
The study analyzed survey data from approximately 10,500 adults in the United States, representing more than 1.1 million people who were being treated for asthma between 2014 and 2023.
Researchers examined how often patients used different types of asthma medications, including long-term controller therapies and quick-relief rescue inhalers. The goal was to determine whether treatment patterns differed across racial and ethnic groups and to identify possible reasons for these differences.
The research team was associated with the University of California, Los Angeles David Geffen School of Medicine. The findings were later discussed in a news release from UCLA and reported by HealthDay News.
The study focused on four main categories of asthma medications:
These medications reduce inflammation in the airways and are considered a first-line daily treatment for long-term asthma control.
These help keep the airways open over time and are often used alongside inhaled corticosteroids.
These relax airway muscles and help improve airflow in more severe cases of asthma.
These are rescue inhalers used for quick relief during asthma attacks. High reliance on SABA can indicate poor long-term asthma control.
The study revealed consistent differences in the use of long-term asthma controller medications across racial and ethnic groups.
Interestingly, there were no major statistically significant differences in SABA use across groups. This suggests that while emergency treatment access may be similar, long-term disease control differs significantly.
Researchers found that the differences in inhaler use were strongly linked to socioeconomic and healthcare access factors. These include:
When these factors were considered, many of the racial differences in medication use decreased significantly. However, the researchers emphasized that these social determinants are themselves shaped by long-standing structural inequalities.
Dr. Utibe Essien from the Utibe Essien explained that even with expanded healthcare coverage through policies such as the Affordable Care Act, gaps in treatment still persist. This suggests that insurance alone is not enough to eliminate disparities in asthma care.
One of the most surprising findings was the larger gap in the use of inhaled corticosteroids. These medications are generally more affordable and widely available compared to other advanced asthma therapies.
This raises important concerns because ICS medications are considered essential for preventing asthma attacks and maintaining long-term lung health. Lower use among minority groups may contribute to worse asthma control and higher risk of complications over time.
Researchers noted that treatment differences may also be influenced by:
The study highlights a broader issue often referred to as pharmacoequity, which focuses on ensuring that all patients have fair access to the most effective medications regardless of race, ethnicity, or income.
Even though healthcare access has expanded in recent years, structural barriers continue to influence treatment outcomes. These barriers can affect:
The findings suggest that improving insurance coverage alone is not sufficient. More targeted interventions are needed to address gaps in care delivery.
Asthma is a chronic condition that requires consistent management. Without proper use of controller inhalers, patients are more likely to experience flare-ups, emergency room visits, and reduced quality of life.
Healthcare systems may need to focus on:
Clinicians may also need to evaluate whether unconscious bias or system-level barriers are influencing prescribing patterns.
This study provides strong evidence that racial and ethnic disparities continue to exist in asthma treatment across the United States. While emergency inhaler use appears similar across groups, long-term controller medication use is significantly lower among Black, Hispanic, and Asian patients compared with white patients.
The findings highlight the importance of addressing not only healthcare access but also the broader social and structural factors that influence treatment outcomes. Achieving equitable asthma care will require coordinated efforts across policy, clinical practice, and patient education.
This article is for informational and educational purposes only. It summarizes findings from medical research and news reports and does not provide medical advice, diagnosis, or treatment. Individual health conditions vary, and readers should consult a qualified healthcare professional for personalized medical guidance.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.